Gilles Pagès
Gilles Pagès is an expert in Biochemistry at Centre Antoine Lacassagne (France). Gilles Pagès has authored 244 publications, the most recent in 2026. SLR score: 1,302 (community average: 125). How the SLR is computed.
LeadR Profile
Biochemistry
Subspecialties: Oncology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026
Number : 244
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers. PMID 42900503 — cells, r factors, growth, vascular endothelial growth factor a, antibodies, vascular resistance, neoplasms, carcinoma, renal cell, neoplasm metastasis, kidney neoplasms, therapeutics, endothelial growth factors, angiogenesis | Mol Oncol | 2026 | 0 |
| Cell-specific ERK2 signaling in vascular smooth muscle cells drives vascular dysfunction and systolic heart failure. PMID 42521079 — cells, muscle cells, muscles, muscle, smooth, heart failure, heart, cardiology, heart failure, systolic, muscle, smooth, vascular, myocytes, smooth muscle, myocytes, cardiac | J Mol Cell Cardiol | 2026 | 0 |
| STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities. PMID 42094611 — nanomedicine, chemistry, pharmaceutical, neoplasms, immunity, therapeutics, apoptosis, physical exertion, protein serine-threonine kinases | Theranostics | 2026 | 0 |
| Reply to Roesler et al. Comment on "Karaulic et al. Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment. Cancers 2025, 17, 3659". PMID 41827737 — neoplasms, medulloblastoma, therapeutics | Cancers (Basel) | 2026 | 0 |
| Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer. PMID 41799185 — cells, nanomedicine, growth, connective tissue, neoplasms, connective tissue growth factor, cell line, kidney neoplasms, therapeutics, tissues | Theranostics | 2026 | 0 |
LeadR Networks
Main global connection map